Adverse Events Associated with Apremilast and Deucravacitinib for Psoriasis: A Pharmacovigilance Study Based on the FAERS Database
Our study offers valuable real-world insights into the safety profiles of apremilast and deucravacitinib. The observed sex differences in adverse events associated with apremilast and deucravacitinib require further investigation in real-world and clinical settings.
Authors
- Xinjin Liu (ORCID: https://orcid.org/0009-0004-2901-8041)
- Y. Xu (ORCID: https://orcid.org/0009-0006-8553-9903)
- Xian Jiang (ORCID: https://orcid.org/0000-0001-5109-6055)
- Linghong Guo (ORCID: https://orcid.org/0000-0002-9248-5070)
Institutions
- Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
Publication Details
- Journal
- Clinical Cosmetic and Investigational Dermatology
- Published
- 2025-05-01
- DOI
- https://doi.org/10.2147/ccid.s439643
- Citations
- 2
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 2.61